A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma

Novel neoadjuvant therapy regimens are warranted for oral squamous cell carcinoma (OSCC). In this phase I trial (NCT04393506), 20 patients with locally advanced resectable OSCC receive three cycles of camrelizumab (200 mg, q2w) and apatinib (250 mg, once daily) before surgery. The primary endpoints...

Descripción completa

Detalles Bibliográficos
Autores principales: Ju, Wu-tong, Xia, Rong-hui, Zhu, Dong-wang, Dou, Sheng-jin, Zhu, Guo-pei, Dong, Min-jun, Wang, Li-zhen, Sun, Qi, Zhao, Tong-chao, Zhou, Zhi-hang, Liang, Si-yuan, Huang, Ying-ying, Tang, Yong, Wu, Si-cheng, Xia, Jing, Chen, Shi-qing, Bai, Yue-zong, Li, Jiang, Zhu, Qi, Zhong, Lai-ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472189/
https://www.ncbi.nlm.nih.gov/pubmed/36104359
http://dx.doi.org/10.1038/s41467-022-33080-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472189/
https://www.ncbi.nlm.nih.gov/pubmed/36104359
http://dx.doi.org/10.1038/s41467-022-33080-8

Ejemplares similares